Dietary fatty acids affect lipid metabolism and estrogen receptor expression in n-methyl-n-nitrosourea-induced rat mammary cancer model

Clinical Laboratory

Volumn 61, Issue 3-4, 2015, Pages 389-395

  Zhang, Feng ^a   Chen, Yuehong ^a   Long, Jingpei ^a   Dong, Lifeng ^a   Wang, Yike ^a   Chen, Yiding ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Breast cancer; Estrogen receptor; Fatty acid binding proteins; Fatty acid synthase; Polyunsaturated fatty acids

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; CD36 ANTIGEN; ESTROGEN RECEPTOR; FATTY ACID BINDING PROTEIN 5; FATTY ACID SYNTHASE; LINOLEIC ACID; METHYLNITROSOUREA; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; UNCLASSIFIED DRUG; CD36 PROTEIN, RAT; EYE PROTEIN; FABP5 PROTEIN, RAT; FATTY ACID; FATTY ACID BINDING PROTEIN; NERVE PROTEIN; UNSATURATED FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAT INTAKE; FEMALE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LIPID DIET; LIPID METABOLISM; NONHUMAN; PROTEIN EXPRESSION; RAT; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DIET; EXPERIMENTAL MAMMARY NEOPLASM; METABOLISM; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; ANTIGENS, CD36; DIET; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE PROTEINS; FATTY ACID SYNTHASES; FATTY ACID-BINDING PROTEINS; FATTY ACIDS; FATTY ACIDS, UNSATURATED; FEMALE; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; NERVE TISSUE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN;

EID: 84929400212     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2014.140901     Document Type: Article

References (38)

1. Strouch MJ, Ding Y, Salabat MR, et al. A high omega-3 fatty acid diet mitigates murine pancreatic precancer development. 2011;165(1):75-81.
2. Korani M, Firoozrai M, Maleki J, et al. Fatty acid composition of serum lipids in patients with type 2 diabetes. Clin Lab 2012;58(11-12):1283-91.
3. Voorrips LE, Brants HA, Kardinaal AF, Hiddink GJ, van den Brandt PA, Goldbohm RA. Intake of conjugated linoleic acid, fat, and other fatty acids in relation to postmenopausal breast cancer: the Netherlands Cohort Study on Diet and Cancer. Am J Clin Nutr 2002;76:873-82.
4. Fay MP, Freedman LS, Cliford CK, Midthune DN. Effect of different types and amounts of fat on the development of mammary tumors in rodents: a review. Cancer Research 1997;57:3979-88.
5. Das UN, Madhavi G, Kumar GS, Padma M, Sangeetha P. Can tumour cell drug resistance be reversed by essential fatty acids and their metabolites? Prostaglandins Leukot Essent Fatty Acids 1998;58:39-54.
6. Hardman WE, Avula CP, Fernandes G, Cameron IN. Three Percent Dietary Fish Oil Concentrate Increased Efficacy of Doxorubicin Against MDA-MB 231 Breast Cancer Xenografts. Clin Cancer Res 2001;7:2041-9.
7. Glatz JF, Luiken JJ, van Bilsen M, van der Vusse GJ. Cellular lipid binding proteins as facilitators and regulators of lipid metabolism. Mol Cell Biochem 2002;239:3-7.
8. Wolfrum C, Borrmann CM, Borchers T, Spener F. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding protein: A signaling path to the nucleus. Proc Natl Acad Sci USA 2001;98:2323-8.
9. Hancke K, Grubeck D, Hauser N, Kreienberg R, Weiss JM. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat 2010;119:367-77.
10. Liu RZ, Graham K, Glubrecht DD, Germain DR, Mackey JR, Godbout R. Association of FABP5 expression with poor survival in triple-negative breast cancer. Am J Pathol 2011;178:997-1008.
11. Zhang H, Rakha EA, Ball GR, et al. The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. Breast Cancer Res Treat 2010;121:41-51.
12. Nozaki S, Tanaka T, Yamashita S. CD36 mediates long-chain fatty acid transport in human myocardium: Complete myocardial accumulation defect of radiolabeled long-chain fatty acid analog in subjects with CD36 deficiency. Mol Cell Biochem 1999;192:129-35.
13. Febbraio M, Abumrad NA, Hajjar DP. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 1999;274:19055-62.
14. Yang YK, Chen M, Loux TJ, Harmon CM. Regulation of FAT/CD36 mRNA gene expression by long chain fatty acids in the differentiated 3T3-L1 cells. Pediatr Surg Int 2007;23:675-83.
15. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-y dependent and independent effects on macrophagegene expression in lipid metabolism and inflammation. Nat Med 2001;7:48-52.
16. Campbel SE, Tandon NN, Woldegiorgis G, Luiken JJ, Glatz JF, Bonen A. A novel function for fatty acid translocase (FAT)/CD36: involvement in long chain fatty acid transfer into the mitochondria. J Biol Chem 2004;279:36235-41.
17. Mashima T, Seimiya H, Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 2009;100:1369-72.
18. Swinnen JV, Roskams T, Joniau S, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 2002;98:19-22.
19. Teran-Garcia M, Adamson AW, Yu G, et al. Polyunsaturated fatty acid suppression of fatty acid synthase (FASN): evidence for dietary modulation of NF-Y binding to the Fasn promoter by SREBP-lc. Biochem J 2007;402:591-600.
20. Vazquez-Martin A, Ortega-Delgado FJ, Fernandez-Real JM, Menendez JA. The Tyrosine Kinase Receptor HER2 (erbB-2): From Oncogenesis to Adipogenesis. J Cell Biochem 2008;105:1147-52.
21. Kalkhoven E, Kwakkenbos-Isbrucker L, de Laat SW, van der Saag PT, van der Burg B. Synthetic progestins induce proliferation of breast tumor cell lines via the progesterone or estrogen receptor. Mol Cell Endocrinol 1994;102, 45-52.
22. Menendez JA, Oza BP, Atlas E, Verma VA, Mehmi I, Lupu R. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells. Oncogene 2004;23:4945-58.
23. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47.
24. Storch J, Corsico B. The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu Rev Nutr 2008;28:73-95.
25. Ishimura S, Furuhashi M, Watanabe Y, et al. Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS One 2013;20;8:e81318.
26. Huynh HT, Larsson C, Narod S, Pollak M. Tumor suppressor activity of the gene encoding mammary-derived growth inhibitor. Cancer Res 1995;55:2225-31.
27. Shi YE, Ni J, Xiao G, et al. Antitumor activity of the novel human breast cancer growth inhibitor, mammary derived growth inhibitor-related gene, MRG. Cancer Res 1997;57:3084-91.
28. Kannan-Thulasiraman P, Seachrist DD, Mahabeleshwar GH, Jain MK, Noy N. Fatty acid-binding protein 5 and PPARbeta/delta are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth. J Biol Chem 2010;285:19106-15.
29. Motomura W, Okumura T, Takahashi N, et al. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiPl in human pancreatic carcinoma cells. Cancer Res 2000;60:5558-64.
30. Febbraio M, Guy E, Cobum C, et al. The impact of overexpression and deficiency of fatty acid translocase (FAT)/CD36. Mol Cell Biochem 2002;239:193-7.
31. Gavrilova O, Haluzik M, Matsusue K, et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 2003;278:34268-76.
32. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001;7:48-52.
33. Orido T, Fujino, Kawashima T, Murayama T. Decrease in uptake of arachidonic acid by indomethacin in LS174T cancer cells; a novel cyclooxygenase-2-inhibition-independent effect. Arch Biochem Biophys 2010;494:78-85.
34. Menendez JA, Ropero S, Mehmi I, et al. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acidinduced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. Int J Oncol 2004;24:1369-83.
35. Moon YS, Latasa MJ, Griffin MJ, Sul HS. Suppression of fatty acid synthase promoter by polyunsaturated fatty acids. J Lipid Res 2002;43:691-8.
36. Zhou W, Tu Y, Simpson PJ, Kuhajda FP. Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cells. Oncogene 2009;28, 2979-87.
37. López M, Lelliott CJ, Tovar S, et al. Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA. Diabetes 2006;55:1327-36.
38. Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Research 2003;63:132-9.